If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

ScaleReadytm, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReadytm, today announced that ImmunoScape Pte. Ltd. (a Singapore-U.S. based TCR-T therapy company) has ...

GSK’s chief commercial officer ... Zhifei also gets the right of first refusal to be the exclusive partner for Arexvy, which is not yet approved in China, but has been cleared in the US ...

With roots in Silicon Valley, Bidgely has over 16 energy patents, $75M+ in funding, retains 30+ data scientists, and brings a passion for AI to utilities serving residential and commercial customers .

Findings showed a noninferior immune response for both vaccines when coadministered compared with separate administration. Topline results were announced from a phase 3 study assessing the immune ...

AREXVY is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older, as well as individuals 50 ...

2 SHINGRIX is approved for the prevention of shingles (herpes zoster) in adults aged 50 years and older. AREXVY is approved for the prevention of lower respiratory tract disease (LRTD) caused by ...